Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Double-blind, Randomized, Multicenter Study to Evaluate the Safety and Efficacy of Evolocumab, Compared With Ezetimibe, in Hypercholesterolemic Subjects Unable to Tolerate an Effective Dose of a HMG-CoA Reductase Inhibitor Due to Muscle Related Side Effects
Brief Summary: The primary objective of this study was to evaluate the effect of 24 weeks of evolocumab administered subcutaneously (SC) every month, compared with ezetimibe, on low-density lipoprotein cholesterol (LDL-C) levels in adults with high cholesterol who are unable to tolerate an effective dose of a statin due to muscle-related side effects (MRSE).


Options:
A: Arm Label: Part A: Atorvastatin 20 mg => Placebo; Type: OTHER; Interventions: Drug: Atorvastatin, Drug: Placebo to Atorvastatin | Arm Label: Part A: Placebo => Atorvastatin 20 mg; Type: OTHER; Interventions: Drug: Atorvastatin, Drug: Placebo to Atorvastatin | Arm Label: Part B: Ezetimibe; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ezetimibe, Other: Placebo to Evolocumab | Arm Label: Part B: Evolocumab; Type: EXPERIMENTAL; Interventions: Other: Placebo to Ezetimibe, Drug: Evolocumab | Arm Label: Part C: Open-label Evolocumab; Type: EXPERIMENTAL; Interventions: Drug: Evolocumab | Intervention Type: DRUG; Name: Atorvastatin; Assigned to Arm(s): Part A: Atorvastatin 20 mg => Placebo, Part A: Placebo => Atorvastatin 20 mg | Intervention Type: DRUG; Name: Placebo to Atorvastatin; Assigned to Arm(s): Part A: Atorvastatin 20 mg => Placebo, Part A: Placebo => Atorvastatin 20 mg | Intervention Type: OTHER; Name: Placebo to Ezetimibe; Assigned to Arm(s): Part B: Evolocumab | Intervention Type: DRUG; Name: Ezetimibe; Assigned to Arm(s): Part B: Ezetimibe | Intervention Type: OTHER; Name: Placebo to Evolocumab; Assigned to Arm(s): Part B: Ezetimibe | Intervention Type: DRUG; Name: Evolocumab; Assigned to Arm(s): Part B: Evolocumab, Part C: Open-label Evolocumab
B: Arm Label: ezetimibe/simvastatin; Type: EXPERIMENTAL; Interventions: Drug: ezetimibe/simvastatin, Drug: Placebo for simvastatin 40 mg | Arm Label: simvastatin; Type: ACTIVE_COMPARATOR; Interventions: Drug: simvastatin, Drug: Placebo for simvastatin 40 mg, Drug: Placebo for ezetimibe 10 mg/simvastatin 40 mg combination | Intervention Type: DRUG; Name: ezetimibe/simvastatin; Assigned to Arm(s): ezetimibe/simvastatin | Intervention Type: DRUG; Name: simvastatin; Assigned to Arm(s): simvastatin | Intervention Type: DRUG; Name: Placebo for simvastatin 40 mg; Assigned to Arm(s): ezetimibe/simvastatin, simvastatin | Intervention Type: DRUG; Name: Placebo for ezetimibe 10 mg/simvastatin 40 mg combination; Assigned to Arm(s): simvastatin
C: Arm Label: Placebo Q2W; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo (for alirocumab), Drug: Lipid Modifying Therapy (LMT) | Arm Label: Alirocumab 150 mg Q2W; Type: EXPERIMENTAL; Interventions: Drug: Alirocumab, Drug: Lipid Modifying Therapy (LMT) | Intervention Type: DRUG; Name: Alirocumab; Assigned to Arm(s): Alirocumab 150 mg Q2W | Intervention Type: DRUG; Name: Placebo (for alirocumab); Assigned to Arm(s): Placebo Q2W | Intervention Type: DRUG; Name: Lipid Modifying Therapy (LMT); Assigned to Arm(s): Alirocumab 150 mg Q2W, Placebo Q2W
D: Arm Label: alirocumab SAR236553 (REGN727) - Dose A; Type: EXPERIMENTAL; Interventions: Drug: alirocumab SAR236553 (REGN727) | Arm Label: alirocumab SAR236553 (REGN727) - Dose B; Type: EXPERIMENTAL; Interventions: Drug: alirocumab SAR236553 (REGN727) | Arm Label: alirocumab SAR236553 (REGN727) - Dose C; Type: EXPERIMENTAL; Interventions: Drug: alirocumab SAR236553 (REGN727) | Intervention Type: DRUG; Name: alirocumab SAR236553 (REGN727); Assigned to Arm(s): alirocumab SAR236553 (REGN727) - Dose A, alirocumab SAR236553 (REGN727) - Dose B, alirocumab SAR236553 (REGN727) - Dose C

Answer: A